Comparative Effects of Pharmacological Treatment on Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials.
Several SGLT2 inhibitors and semaglutide reduced hospitalizations for heart failure, though no drug prevented death better than others.
This systematic review and network meta-analysis of randomized trials examined comparative effects of pharmacological treatment on heart failure with mildly reduced or preserved ejection fraction: a systematic review and network meta-analysis of randomized controlled trials. The PubMed abstract reports across 20 randomized trials, no drug-level differences were found for cardiovascular or all-cause mortality, while several sglt2 inhibitors and semaglutide reduced heart-failure hospitalization relative to exenatide.
What the study was
- Study design
- Systematic review and network meta-analysis of randomized trials
- Population
- Patients with heart failure with mildly reduced or preserved ejection fraction
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Drugs
Why it surfaced
Score reflects the systematic review and network meta-analysis of randomized trials design and relevance to Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk; classification is limited to PubMed title, metadata, and abstract evidence.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.